Publications (135) ISABEL CASTREJÓN FERNÁNDEZ publications

2024

  1. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register

    Seminars in Arthritis and Rheumatism, Vol. 64

  2. Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries

    Arthritis Care and Research, Vol. 76, Núm. 11, pp. 1558-1565

  3. Correction to: Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care (BMC Rheumatology, (2024), 8, 1, (31), 10.1186/s41927-024-00401-x)

    BMC Rheumatology

  4. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  5. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

    RMD Open, Vol. 10, Núm. 3

  6. Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

    Arthritis Research and Therapy, Vol. 26, Núm. 1

  7. Interrater reliability of RheuMetric checklist scales for physician global assessment, inflammation, damage and patient distress

    Rheumatology Advances in Practice, Vol. 8, Núm. 4

  8. Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 9, pp. 1189-1199

  9. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry

    The Journal of rheumatology, Vol. 51, Núm. 9, pp. 877-883

  10. Macrophage re-programming by JAK inhibitors relies on MAFB

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  11. Opioids and fibromyalgia: frequency of use and factors associated with increased consumption in patients remitted to a tertiary care center

    BMC Musculoskeletal Disorders, Vol. 25, Núm. 1

  12. Patient-reported outcome measures for systemic lupus erythematosus: an expert Delphi consensus to guide implementation in routine care

    BMC Rheumatology, Vol. 8, Núm. 1

  13. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 65

  14. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

  15. Recording of non-musculoskeletal manifestations, comorbidities and safety outcomes in European spondyloarthritis registries: A survey

    Rheumatology Advances in Practice, Vol. 8, Núm. 4

  16. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching

    Rheumatology (United Kingdom), Vol. 63, Núm. 7, pp. 1882-1892

  17. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598

  18. Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis

    Reumatologia Clinica, Vol. 20, Núm. 8, pp. 423-439

2023

  1. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Correction: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry (Arthritis Research & Therapy, (2023), 25, 1, (86), 10.1186/s13075-023-03045-3)

    Arthritis Research and Therapy